Market Cap (In USD)
688.2 Million
Revenue (In USD)
-
Net Income (In USD)
-188.91 Million
Avg. Volume
1.18 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 11.94-18.07
- PE
- -6.66
- EPS
- -1.02
- Beta Value
- -1.518
- ISIN
- US23954D1090
- CUSIP
- 23954D109
- CIK
- 1845337
- Shares
- 101355000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jeremy Bender M.B.A., Ph.D.
- Employee Count
- -
- Website
- https://dayonebio.com
- Ipo Date
- 2021-05-27
- Details
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
More Stocks
-
RNK
-
1780
-
LPX
-
4242
-
SRPT
-
BGS
-
ARYCArrayit Corporation
ARYC
-
BAKKBakkavor Group plc
BAKK